Tirzepatide
While introduced as a diabetes medication, is now known as a popular weight loss injection, helping countless people worldwide take control of their weight once and for all. Not only does this prescription injection help improve weight, but it has been improving blood sugar (glucose) in adults with type 2 diabetes for decades. Now, studies show that Tirzepatide is an excellent option for weight loss. It can help people lose weight and maintain a healthy weight, reduce hunger, reduce cravings, regulate blood sugar, improve metabolic health, and more. This medication is a dual GIP and GLP-1 receptor, making it the first drug of its kind. As a result, the innovative weight management tool is a game changer for many people who have tried multiple attempts to lose weight and improve their health with no luck.
Benefits of Tirzepatide for Weight Loss
Tirzepatide has significantly positive benefits for weight loss. These benefits include:
Helps improve the health conditions of patients with type 2 diabetes
Lower blood sugar without any increase in hypoglycemia.
Achieves optimal metabolic health goals
How Tirzepatide is Enhancing Weight Loss Treatment
Tirzepatide works like similar Glucagon-like peptide-1 (GLP-1) weight loss treatments, like Semaglutide injections. However, there is a big difference between the two formulas. Tirzepatide has an extra molecule to give it an edge when helping people lose weight. The dual-action formula mimics the action of not one but two incretin hormones involved in blood sugar control: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). The unique dual action makes Tirzepatide the first-in-class medication that acts on both receptors.
​
Tirzepatide, like Semaglutide, has undergone countless clinical studies and trials to test its effectiveness in not just treating diabetes but also weight loss. There are several studies and trials that back the effectiveness of this drug to help people lose weight and improve their health outside of blood sugar levels.
​
One study shows that when Tirzepatide is taken with or without other diabetes medications, the percentage of people taking it reaches an A1C of less than 7%, ranging from 75% (5mg) to 90% (10mg). People with an average starting A1C of 7.9% to 8.6% across the 5mg, 10mg, and 15mg doses.
The 40-week study was completed to show if the medication plus basal insulin worked better than basal insulin alone. Of the 90% of people taking Tirzepatide plus basal insulin, each achieves an A1C of under 7%.